DGAP-News: Press Release: 4SC presents results from analysis of biomarkers and prognostic factors in Phase II SHELTER …

DGAP-News: 4SC AG / Key word(s): Miscellaneous Press Release: 4SC presents results from analysis of biomarkers and prognostic factors in Phase II SHELTER trial with resminostat in advanced liver cancer (HCC)

13.09.2013 / 07:30

---------------------------------------------------------------------

Press Release

4SC presents results from analysis of biomarkers and prognostic factors in Phase II SHELTER trial with resminostat in advanced liver cancer (HCC)

- Identification and further characterization of novel potentially predictive biomarker ZFP64 indicative for survival upon treatment with resminostat in patients with advanced HCC

- High baseline expression of ZFP64 in peripheral blood (observed in about 2/3 of patients) correlates with doubling of median overall survival compared to low baseline ZFP64

- Additional patient baseline characteristics influencing overall survival in HCC identified

- Both ZFP64 biomarker analysis and patient baseline characteristics to be integrated for patient stratification in planned pivotal programme with resminostat in advanced HCC

- Oral presentation of detailed results at ILCA conference, 15 Sept. 2013, Washington D.C.

Link:
DGAP-News: Press Release: 4SC presents results from analysis of biomarkers and prognostic factors in Phase II SHELTER ...

Related Posts

Comments are closed.